Drug Interaction Report

Nirmatrelvir and Dabigatran Etexilate: Interaction Details

A pharmacist-reviewed analysis of the Nirmatrelvir and Dabigatran Etexilate interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Dabigatran Etexilate

No brand names on record
+

Nirmatrelvir

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 72 documented Nirmatrelvir interactions, 55 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Increased dabigatran exposure and increased risk of bleeding

Interaction Deep Dive

Concomitant use of dabigatran and a P-gp inhibitor may increase dabigatran exposure and risk of bleeding. P-gp inhibition and renal impairment are the major risk factors for increased dabigatran exposure, therefore adjustments may be necessary. For treatment of, recurrence risk reduction of, or prophylaxis after hip replacement surgery of DVT or pulmonary embolism (PE), avoid coadministration if CrCl is less than 50 mL/min. For stroke and systemic embolism risk reduction in non-valvular atrial fibrillation, avoid coadministration in severe renal impairment (CrCl less than 30 mL/min); in moderate impairment (CrCl 30 to 50 mL/min), reduce dabigatran to 75 mg twice daily if concomitant use of dronedarone or systemic ketoconazole is necessary. With CrCl 50 mL/min or greater, separate the timing of administration by several hours if dabigatran is used with a P-gp inhibitor1. Caution may be necessary with coadministration of dabigatran and moderate to strong P-gp inhibitors regardless of kidney function 2, and consider avoiding use of a P-gp inhibitor with dabigatran 3.

Why it happens (mechanism)

Inhibition of P-gp-mediated efflux transport of dabigatran by ritonavir

Common questions

Can I take Nirmatrelvir and Dabigatran Etexilate together?

Increased dabigatran exposure and increased risk of bleeding Always confirm with your pharmacist or prescriber before making any change.

How serious is the Nirmatrelvir and Dabigatran Etexilate interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Nirmatrelvir or Dabigatran Etexilate need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (3)

  1. Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2020. DailyMed
  2. Pham P, Schmidt S, Lesko L, et al: Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020; 3(4):e203593-. DOI
  3. Pfizer Labs: Fact sheet for healthcare providers: Emergency Use Authorization for PAXLOVID(TM). US Food & Drug Administration (FDA). Silver Spring, MD. 2022.
Was this write-up helpful?
Dabigatran Etexilate

Keep reading about Dabigatran Etexilate

All Dabigatran Etexilate interactions (314) Dabigatran Etexilate drug information
Also serious with: Defibrotide Levoketoconazole Defibrotide Injection Dexketoprofen
Nirmatrelvir

Keep reading about Nirmatrelvir

All Nirmatrelvir interactions (72)
Also serious with: Finerenone Midazolam Injection Flecainide Dihydroergotamine Injection

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.